MDR-TB Treatment & Prevention

Discussion Brief

Health providers who do not have access to second-line drugs (SLD) are deeply frustrated at their inability to offer adequate treatment to patients diagnosed with multidrug-resistant tuberculosis (MDR-TB). However, there are many factors besides access to drugs that are key to MDR-TB treatment, and providers should work with their National TB Programs (NTPs) in order to build a sustainable and effective delivery system that allows for better patient retention thus preventing more drug resistance and poor treatment outcome.

Members in Indonesia, the Philippines, Taiwan and the Netherlands confront this challenge, exchanging experience on their work with NTPs to develop a comprehensive MDR-TB delivery system.
Sign in to read complete brief

• How to Prevent Cholera: Free cholera fact sheets in 4 languages from Hesperian
• Multidrug-Resistant Tuberculosis (TB) Resistant to Fluoroquinolones and Streptomycin but Susceptible to Second-Line Injection Therapy Has a Better Prognosis than Extensively Drug-Resistant TB
• Treatment of malaria restricted to labratory-confirmed cases: a prospective cohort study in Ugandan Children
• TB Country Guides
• Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study

• [MDR-TB Treatment & Prevention] in Afghanistan
• RE: [MDR-TB Treatment & Prevention] [MDR-TB Treatment & Prevention] in Afghanistan
• sputum collection booth in Prison
• WHO/USAID MDR-TB Planning Toolkit--version 2 now available
• TB diagnostics market dynamics